In BC, HER2 gene is overexpressed in about 20% of invasive forms, and as a prognostic factor, HER2 + is associated with high rates of recurrence and mortality, being a predictive factor for treatment benefits from HER2-targeting agents like trastuzumab, lapatinib, and pertuzumab [8]. Here, ERBB2 is linked to breast cancer.